Procalcitonin levels in community-acquired pneumonia-correlation with aetiology and severity

Scandinavian Journal of Infectious Diseases

Volumn 46, Issue 11, 2014, Pages 787-791

  Johansson, Niclas ^a   Kalin, Mats ^a   Backman Johansson, Carolina ^a   Larsson, Anders ^b   Nilsson, Kristina ^a   Hedlund, Jonas ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Bacterial pneumonia; C reactive protein; Pneumonia severity index; Procalcitonin; Viral

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN; BIOLOGICAL MARKER; CALCITONIN; PROTEIN PRECURSOR;

ARTICLE; BACTEREMIA; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MIXED INFECTION; PNEUMONIA SEVERITY INDEX; VIRUS ETIOLOGY; ADOLESCENT; ADULT; AGED; BACTERIAL PNEUMONIA; BACTERIUM; BLOOD; COMMUNITY ACQUIRED INFECTION; FEMALE; ISOLATION AND PURIFICATION; LENGTH OF STAY; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BACTERIA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SEVERITY OF ILLNESS INDEX;

EID: 84912047611     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2014.945955     Document Type: Article

References (21)

1. Lim WS, Baudouin SV, G eorge RC, H ill A T, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64(Suppl 3):iii1-55
2. Mizgerd JP. A cute lower respiratory tract infection. N Engl J Med 2008;358:716-27
3. Deng JC, S tandiford TJ. The systemic response to lung infection. Clin Chest Med 2005;26:1-9
4. Menendez R, Sahuquillo-Arce JM, R eyes S, Martinez R , Polverino E, Cilloniz C, et al. Cytokine activation patternSand biomarkers are Influenced by microorganisms in community- acquired pneumonia. Chest 2012;141:1537-45
5. Muller B, Becker KL. Procalcitonin: how a hormone became Amarker and mediator of sepsis. Swiss Med Wkly 2001;131:595-602
6. hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000;28:68-73
7. Kruger S, Ewig S, Papassotiriou J, Kunde J, Marre R , von Baum H, et al. Infl ammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res 2009;10:65
8. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacteriaLinfection: a systematic revieWand meta-analysis. Clin Infect Dis 2004;39:206-17
9. Tiveljung-Lindell A, Rotzen-Ostlund M, Gupta S, Ullstrand R , Grillner L, Zweygberg-Wirgart B, et al. Development and implementation of Amolecular diagnostic platform for daily rapid detection of 15 respiratory viruses. J Med Virol 2009;81:167-75
10. Ruuskanen O, Lahti E, Jennings LC, M urdoch DR. V iral pneumonia. Lancet 2011;377:1264-75
11. Welti M, Jaton K, Altwegg M, Sahli R, Wenger A, Bille J. Development of Amultiplex real-time quantitative PCR assay to detect Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae in respiratory tract secretions. Diagn MicrobioLinfect Dis 2003;45:85-95
12. Kais M, Spindler C, Kalin M, Ortqvist A, Giske CG. Quantitative detection of Streptococcus pneumoniae, Haemophilus Influenzae, and Moraxella catarrhalis in lower respiratory tract samples by real-time PCR. Diagn MicrobioLinfect Dis 2006;55:169-78
13. Johansson N, Kalin M, Tiveljung-Lindell A, Giske C G , Hedlund J. EtiologYof community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010;50:202-9
14. Johansson N, Kalin M, Giske C G, Hedlund J. Q uantitative detection of Streptococcus pneumoniae from sputum samples with real-time quantitative polymerase chain reaction for etiologic diagnosis of community-acquired pneumonia. Diagn MicrobioLinfect Dis 2008;60:255-61
15. Johansson N, Kalin M, Hedlund J. ClinicaLimpact of combined viral and bacteriaLinfection in patients with community- acquired pneumonia. Scand J Infect Dis 2011;43:609-15
16. Fine M J, Auble TE, Y ealy D M, Hanusa B H, Weissfeld L A , Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50
17. Lacoma A, Rodriguez N, Prat C, Ruiz-Manzano J, Andreo F, Ramirez A, et al. Usefulness of consecutive biomarkers measurement in the management of communityacquired pneumonia. Eur J Clin MicrobioLinfect Dis 2012;31:825-33
18. MasiAm, Gutierrez F, Shum C, Padilla S, Navarro J C, Flores E , et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005;128:2223-9
19. Schuetz P, Chiappa V, Briel M, Greenwald J L. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trialSand recommendations for clinical algorithms. Arch Intern Med 2011;171 : 1322-31
20. Boussekey N, LeroYo, Alfandari S, Devos P, Georges H, Guery B. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006;32:469-72
21. Muller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, et al. DiagnostiCand prognostiCaccuracYof clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007;7:10